CVE:IPA

ImmunoPrecise Antibodies Competitors

C$13.58

-1.07 (-7.30 %)

(As of 04/14/2021 03:59 PM ET)

Add

Compare

Today's Range

C$13.58

Now: C$13.58▼

C$14.85

50-Day Range

C$10.99

MA: C$14.45▼

C$17.50

52-Week Range

C$3.75

Now: C$13.58▼

C$26.25

Volume25,818 shs

Average Volume64,158 shs

Market CapitalizationC$259.09 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

ImmunoPrecise Antibodies (CVE:IPA) Vs. BLU, TH, NRI, PLI, MDNA, and NEPT

Should you be buying IPA stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to ImmunoPrecise Antibodies, including BELLUS Health (BLU), Theratechnologies (TH), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), ProMetic Life Sciences (PLI), Medicenna Therapeutics (MDNA), and Neptune Wellness Solutions (NEPT).

ImmunoPrecise Antibodies vs. BELLUS Health Stock

BELLUS Health (TSE:BLU) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares BELLUS Health and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BELLUS Health	N/A	N/A	N/A
ImmunoPrecise Antibodies	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BELLUS Health and ImmunoPrecise Antibodies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BELLUS Health	0	1	2	0	2.67
ImmunoPrecise Antibodies	0	0	0	0	N/A

Earnings & Valuation

This table compares BELLUS Health and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BELLUS Health	C$15,000.00	29,559.16	C$-42,145,306.00	C($0.54)	-10.52
ImmunoPrecise Antibodies	C$17.18 million	15.08	C$-4,082,906.00	C($0.21)	-63.46

ImmunoPrecise Antibodies has higher revenue and earnings than BELLUS Health. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

ImmunoPrecise Antibodies vs. Theratechnologies Stock

Theratechnologies (TSE:TH) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Theratechnologies and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theratechnologies	N/A	N/A	N/A
ImmunoPrecise Antibodies	N/A	N/A	N/A

Earnings & Valuation

This table compares Theratechnologies and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theratechnologies	C$66.05 million	6.48	C$-34,627,329.00	C($0.37)	-12.36
ImmunoPrecise Antibodies	C$17.18 million	15.08	C$-4,082,906.00	C($0.21)	-63.46

ImmunoPrecise Antibodies has lower revenue, but higher earnings than Theratechnologies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Theratechnologies and ImmunoPrecise Antibodies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theratechnologies	0	2	0	0	2.00
ImmunoPrecise Antibodies	0	0	0	0	N/A

Theratechnologies currently has a consensus price target of C$3.75, indicating a potential downside of 17.76%. Given Theratechnologies' higher probable upside, research analysts clearly believe Theratechnologies is more favorable than ImmunoPrecise Antibodies.

ImmunoPrecise Antibodies vs. Nuvo Pharmaceuticals Inc. (NRI.TO) Stock

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Earnings and Valuation

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvo Pharmaceuticals Inc. (NRI.TO)	C$76.09 million	5.35	C$-6,980,844.00	C($0.61)	-58.36
ImmunoPrecise Antibodies	C$17.18 million	15.08	C$-4,082,906.00	C($0.21)	-63.46

ImmunoPrecise Antibodies has lower revenue, but higher earnings than Nuvo Pharmaceuticals Inc. (NRI.TO). ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals Inc. (NRI.TO), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuvo Pharmaceuticals Inc. (NRI.TO)	N/A	N/A	N/A
ImmunoPrecise Antibodies	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations for Nuvo Pharmaceuticals Inc. (NRI.TO) and ImmunoPrecise Antibodies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvo Pharmaceuticals Inc. (NRI.TO)	0	0	1	0	3.00
ImmunoPrecise Antibodies	0	0	0	0	N/A

ImmunoPrecise Antibodies vs. ProMetic Life Sciences Stock

ProMetic Life Sciences (TSE:PLI) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Profitability

This table compares ProMetic Life Sciences and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProMetic Life Sciences	N/A	N/A	N/A
ImmunoPrecise Antibodies	N/A	N/A	N/A

Earnings & Valuation

This table compares ProMetic Life Sciences and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMetic Life Sciences	C$39.91 million	0.00	C$-1,470,117,780.00	C($63.06)	N/A
ImmunoPrecise Antibodies	C$17.18 million	15.08	C$-4,082,906.00	C($0.21)	-63.46

ImmunoPrecise Antibodies has lower revenue, but higher earnings than ProMetic Life Sciences. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for ProMetic Life Sciences and ImmunoPrecise Antibodies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProMetic Life Sciences	0	0	0	0	N/A
ImmunoPrecise Antibodies	0	0	0	0	N/A

ImmunoPrecise Antibodies vs. Medicenna Therapeutics Stock

Medicenna Therapeutics (TSE:MDNA) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Medicenna Therapeutics and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medicenna Therapeutics	N/A	N/A	N/A
ImmunoPrecise Antibodies	N/A	N/A	N/A

Valuation and Earnings

This table compares Medicenna Therapeutics and ImmunoPrecise Antibodies' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicenna Therapeutics	N/A	N/A	N/A	C($0.31)	-16.41
ImmunoPrecise Antibodies	C$17.18 million	15.08	C$-4,082,906.00	C($0.21)	-63.46

Medicenna Therapeutics has higher earnings, but lower revenue than ImmunoPrecise Antibodies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Medicenna Therapeutics and ImmunoPrecise Antibodies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicenna Therapeutics	0	0	0	0	N/A
ImmunoPrecise Antibodies	0	0	0	0	N/A

Summary

ImmunoPrecise Antibodies beats Medicenna Therapeutics on 2 of the 3 factors compared between the two stocks.

ImmunoPrecise Antibodies vs. Neptune Wellness Solutions Stock

Neptune Wellness Solutions (TSE:NEPT) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Neptune Wellness Solutions and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neptune Wellness Solutions	N/A	N/A	N/A
ImmunoPrecise Antibodies	N/A	N/A	N/A

Valuation and Earnings

This table compares Neptune Wellness Solutions and ImmunoPrecise Antibodies' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neptune Wellness Solutions	C$52.78 million	4.89	C$-223,415,550.00	C($1.35)	-1.16
ImmunoPrecise Antibodies	C$17.18 million	15.08	C$-4,082,906.00	C($0.21)	-63.46

ImmunoPrecise Antibodies has lower revenue, but higher earnings than Neptune Wellness Solutions. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Neptune Wellness Solutions and ImmunoPrecise Antibodies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neptune Wellness Solutions	0	0	1	0	3.00
ImmunoPrecise Antibodies	0	0	0	0	N/A

Neptune Wellness Solutions currently has a consensus price target of C$4.63, suggesting a potential upside of 196.47%. Given Neptune Wellness Solutions' higher possible upside, equities analysts clearly believe Neptune Wellness Solutions is more favorable than ImmunoPrecise Antibodies.

Summary

Neptune Wellness Solutions beats ImmunoPrecise Antibodies on 4 of the 7 factors compared between the two stocks.